Revenue qualityDanger
매출 흑자인데 영업CF 적자 (OCF/매출 -2488%). 통계적 정황 신호이며 회계부정 단정이 아닙니다.
vTv Therapeutics Class A financial statements
VTV 테라퓨틱스NASDAQ:VTVT · Nasdaq · Healthcare · sector #17$31.01+3.26%
2026-10-07 closevTv Therapeutics Class A's published financial data is dated 2026-10-04. 2024 revenue was $1M. 2024 operating profit was −$24M.
Reported results
Financial safety
Reference indicatorAs of 2024Distress zoneFinancial-metric reference signal
Altman Z'' zoneZ'' -23.65
Distress
Grey
Safe
- Altman Z''
- -23.65
- Beneish M-Score
- —
- Sloan accrual
- 17.89%
Statistical flag unavailable
부실·조작 위험을 나타내는 사실 지표입니다. 투자 조언이 아니며, 검증 전이라 참고용입니다.
Factual information, not investment advice.
Earnings quality · Piotroski F-Score
5/9Moderate
Piotroski measures year-over-year financial improvement, not absolute quality.
Financial improvement score5/9
Profitability
- Positive ROANot passed
- Positive OCFNot passed
- Improving ΔROAPass
- Accruals (OCF > net income)Not passed
Leverage & liquidity
- Lower debtPass
- Higher current ratioPass
- No new sharesPass
Efficiency
- Higher gross marginNot passed
- Higher asset turnoverPass
Calculation note: F7(신주)은 equity/asset 유지로 근사
Already-stable companies may score lower when year-over-year improvement is limited.
Factual information, not investment advice.
Forensic signals
Anomaly and structural signals observed in the financial statements.
Factual information, not investment advice.
Risk sensitivity — adverse assumptions
Metric changes under stated assumptions; not a forecast or investment advice.
Base metrics
- Operating margin
- -2,377.6%
- Interest coverage
- —
- Return on equity (ROE)
- -151.3%
Operating margin −5pp
Operating lossInterest coverageBase — adverse case —
Return on equity (ROE)Base -151.3% adverse case -149%
Revenue −15%
TolerableInterest coverageBase — adverse case —
Return on equity (ROE)Base -151.3% adverse case -126.4%
Quantus Signal · live data · not investment advice · Privacy Policy